Sagimet Biosciences (SGMT) Free Cash Flow (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Free Cash Flow of -$8.6 million for Q1 2026, up 40.76% year-over-year from -$6.1 million in Q1 2025, and up 27.23% quarter-over-quarter from -$11.8 million in Q4 2025.
Sagimet Biosciences (SGMT) Free Cash Flow (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Free Cash Flow history runs 5 years deep, the most recent figure standing at -$8.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 40.76% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at -$39.7 million (up 21.74% YoY), while the FY2025 annual figure was -$45.6 million, down 7.58% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$8.6 million, up from -$11.8 million in the prior quarter.
- The five-year high for Free Cash Flow was -$3000.0 in Q2 2022, with the low at -$19.6 million in Q3 2024.
- The 5-year median for Free Cash Flow is -$7.3 million (2022), against an average of -$8.4 million.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow sank 190566.67% in 2023, then jumped 47.98% in 2025.
- Sagimet Biosciences' Free Cash Flow stood at -$7.5 million in 2022, then advanced by 4.96% to -$7.1 million in 2023, then slumped by 55.64% to -$11.0 million in 2024, then fell by 7.34% to -$11.8 million in 2025, then rose by 27.23% to -$8.6 million in 2026.
- Business Quant data shows SGMT's Free Cash Flow at -$8.6 million in Q1 2026, -$11.8 million in Q4 2025, and -$10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | -11.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.10 Mn |
| Jun 30, 2026 | -11.10 Mn |
| Mar 31, 2026 | -8.61 Mn |
| Mar 31, 2026 | -8.61 Mn |
| Dec 31, 2025 | -11.83 Mn |
| Dec 31, 2025 | -11.83 Mn |
| Sep 30, 2025 | -10.18 Mn |
| Sep 30, 2025 | -10.18 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Mar 31, 2025 | -14.54 Mn |
| Mar 31, 2025 | -14.54 Mn |
| Dec 31, 2024 | -11.02 Mn |
| Dec 31, 2024 | -11.02 Mn |
| Sep 30, 2024 | -19.57 Mn |
| Sep 30, 2024 | -19.57 Mn |
| Jun 30, 2024 | -5.63 Mn |
| Jun 30, 2024 | -5.63 Mn |
| Mar 31, 2024 | -6.21 Mn |
| Mar 31, 2024 | -6.21 Mn |